GE

273.63

-0.32%↓

RTX

159.9

+0.15%↑

CAT

433.04

+0.46%↑

BA

235.71

+0.5%↑

GEV.US

622.92

-0.49%↓

GE

273.63

-0.32%↓

RTX

159.9

+0.15%↑

CAT

433.04

+0.46%↑

BA

235.71

+0.5%↑

GEV.US

622.92

-0.49%↓

GE

273.63

-0.32%↓

RTX

159.9

+0.15%↑

CAT

433.04

+0.46%↑

BA

235.71

+0.5%↑

GEV.US

622.92

-0.49%↓

GE

273.63

-0.32%↓

RTX

159.9

+0.15%↑

CAT

433.04

+0.46%↑

BA

235.71

+0.5%↑

GEV.US

622.92

-0.49%↓

GE

273.63

-0.32%↓

RTX

159.9

+0.15%↑

CAT

433.04

+0.46%↑

BA

235.71

+0.5%↑

GEV.US

622.92

-0.49%↓

Search

Ocugen Inc

Cerrado

1.04 0.97

Resumen

Variación precio

24h

Actual

Mínimo

1.04

Máximo

1.05

Métricas clave

By Trading Economics

Ingresos

611K

-15M

Ventas

-108K

1.4M

Margen de beneficio

-1,073.489

Empleados

95

EBITDA

724K

-13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+380.77% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

6.5M

325M

Apertura anterior

0.07

Cierre anterior

1.04

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ocugen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ago 2025, 22:51 UTC

Ganancias

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Ganancias

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Charlas de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Ganancias

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Ganancias

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Ganancias

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Ganancias

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Ganancias

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Ganancias

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Ganancias

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Ganancias

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Ganancias

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Ganancias

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparación entre iguales

Cambio de precio

Ocugen Inc Esperado

Precio Objetivo

By TipRanks

380.77% repunte

Estimación a 12 meses

Media 5 USD  380.77%

Máximo 8 USD

Mínimo 1 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.